SPY332.80-2.77 -0.83%
DIA277.19-0.95 -0.34%
IXIC10,782.82-185.53 -1.69%
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 23h ago
AVEO Pharmaceuticals Q2 EPS $(0.42) Down From $(0.02) YoY, Sales $749.00K Up From $703.00K YoY
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.42) per share. This is a 2000 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $749.00 thousand
Benzinga · 1d ago
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility
AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period
Business Wire · 1d ago
AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update.
Business Wire · 1d ago
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 5d ago
AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin
AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an
Business Wire · 6d ago
New Strong Sell Stocks for July 1st
Zacks · 07/01 14:16
AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,0
Business Wire · 06/19 20:05
Deerfield Management Reports 6.09% Passive Stake In AVEO Pharmaceuticals
Benzinga · 06/19 16:14
NCLH, DKNG among premarket losers
Seeking Alpha - Article · 06/17 12:18
AVEO Prices 8.5M Share Public Offering of Common Stock @$5.25/Share
AVEO Oncology (NASDAQ: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share.
Benzinga · 06/17 09:44
AVEO prices equity offering at $5.25
Seeking Alpha - Article · 06/17 08:44
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock
Business Wire · 06/17 03:38
AVEO Announces $40M Proposed Common Stock Offering
Benzinga · 06/15 20:05
AVEO Announces Proposed Public Offering of Common Stock
AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an addi
Business Wire · 06/15 20:05
Aveo Oncology: Managing A Position Following Positive ASCO Data Readout
Seeking Alpha - Article · 06/07 18:29
Hedge Funds Never Been Less Bullish On AVEO Pharmaceuticals, Inc. (AVEO)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inve
Insider Monkey · 06/04 23:01
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
Zacks · 06/02 16:41
Aveos Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Cancer
SmarterAnalyst · 06/02 09:00
FDA accepts Aveo application for tivozanib for kidney cancer
The FDA accepts for review AVEO Oncology's (AVEO -2.9%) marketing application seeking approval of tivozanib for relapsed/refractory renal cell carcinoma. T
seekingalpha · 06/01 23:12